References
- World Health Organization. Depression fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/depression. Accessed December 16, 2021.
- McLachlan G. Treatment resistant depression: what are the options? BMJ. 2018;363:k5354. doi:10.1136/bmj.k5354
- European Medicines Agency. Clinical investigation of medicinal products in the treatment of depression. Available from: https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-depression. Accessed December 16, 2021.
- McCrone P, Rost F, Keeser L, et al. The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health. 2018;27(6):567–573. doi:10.1080/09638237.2017.1417562
- Spravato® (esketamine hydrochloride). Summary of product characteristics. High Wycombe, UK: Janssen-Cilag Ltd; 2021.
- Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238–249. doi:10.1038/nm.4050
- Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4(5):409–418. doi:10.1016/S2215-0366(17)30015-9
- Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015;23(1):1–21. doi:10.1037/a0038550
- Whiting D, Cowen PJ. Drug information update: agomelatine. Psychiatrist. 2013;37(11):356–358. doi:10.1192/pb.bp.113.043505
- Valdoxan® (agomelatine). Summary of product characteristics. Suresnes, France: Servier Laboratories Ltd; 2021.
- Mirtazapine 15mg tablets. Summary of product characteristics. Ruislip, UK: Milpharm Ltd; 2021.
- Duman RS. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci. 2014;16(1):11–27. doi:10.31887/DCNS.2014.16.1/rduman
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibility dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active controlled study. Am J Psychiatry. 2019;176(6):428–438. doi:10.1176/appi.ajp.2019.19020172
- Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903. doi:10.1001/jamapsychiatry.2019.1189
- Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a Phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81(3):19m12891. doi:10.4088/JCP.19m12891
- Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression. Am J Geriatr Psychiatry. 2020;28(2):121–141. doi:10.1016/j.jagp.2019.10.008
- Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–630. doi:10.1093/ijnp/pyz039
- FDA. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. Available from: www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Accessed December 16, 2021.
- Health Canada. Product information: Spravato. Available from: https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98903. Accessed December 16, 2021.
- Esketamine (Spravato). Scottish Medicines Consortium. Available from: https://www.scottishmedicines.org.uk/medicines-advice/esketamine-spravato-full-smc2258. Accessed December 16, 2021.
- López-Díaz Á, Murillo-Izquierdo M, Moreno-Mellado E. Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective. Br J Psychiatry. 2019;215(2):447–448. doi:10.1192/bjp.2019.102
- Pharmaceutical Services Negotiating Committee. Controlled Drug regulations. Available from: https://psnc.org.uk/contract-it/pharmacy-regulation/controlled-drug-regulations. Accessed December 16, 2021.
- López-Díaz Á, Rendón de Lope L, De la Vega Sánchez D. Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: towards registry-based surveillance systems. J Affect Disord. 2022;297:145–147. doi:10.1016/j.jad.2021.10.036